drugset / Trial / NCT04896528

Efficacy and Safety of Avatrombopag in Cancer Patients With Thrombocytopenia

NCT04896528

Phase 2 Unknown 30 enrolled Peking Union Medical College Hospital
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of Avatrombopag in patients with thrombocytopenia induced by targeted therapy and immunotherapy combination treatment, and provide evidence-based medication for the clinical use of Avatrombopag in patients with PC ≤50×109/L

Timeline

Start
2021-06-06
Primary completion
2021-12-31
Completion
2021-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Avatrombopag Small molecule 60 mg Oral

Indications